What's Happening?
Codexis, Inc., a leader in enzymatic solutions for therapeutics manufacturing, is set to present new data on its ECO Synthesis® Manufacturing Platform at the TIDES USA conference in Boston. The company will showcase advancements in RNA manufacturing, focusing
on controlling phosphorothioate stereochemistry and improving ligation efficiency. These developments are crucial as RNAi therapies expand into larger indications, requiring scalable and high-quality manufacturing processes. Codexis will also host a panel discussion on stereochemistry in RNAi manufacturing, featuring industry experts.
Why It's Important?
The advancements presented by Codexis are significant for the pharmaceutical industry, particularly in the field of RNA therapeutics. As RNAi therapies gain traction, the need for efficient and scalable manufacturing solutions becomes critical. Codexis' innovations could lead to more sustainable and cost-effective production processes, benefiting pharmaceutical companies and potentially accelerating the development of new therapies. This could have a profound impact on the treatment of various diseases, enhancing the industry's ability to deliver effective solutions to patients.
What's Next?
Following the conference, Codexis is likely to continue its engagement with regulatory bodies to further develop its enzymatic platform. The company's focus on sustainability and efficiency in RNA manufacturing positions it well to collaborate with pharmaceutical companies seeking to optimize their production processes. The outcomes of the panel discussion and presentations at TIDES USA may influence future industry standards and practices, potentially leading to broader adoption of Codexis' technologies.
